Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML). - Wikidata - awgldk - TriplyDB

Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML).

Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML).

http://www.wikidata.org/entity/Q37104378

about

Aberrant splicing and drug resistance in AML Naturally Occurring Isothiocyanates Exert Anticancer Effects by Inhibiting Deubiquitinating Enzymes Acid ceramidase is upregulated in AML and represents a novel therapeutic target.SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains Myeloid cell leukemia-1 is associated with tumor progression by inhibiting apoptosis and enhancing angiogenesis in colorectal cancer.Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.Dihydroartemisinin and its derivative induce apoptosis in acute myeloid leukemia through Noxa-mediated pathway requiring iron and endoperoxide moiety.Rational Combinations of Targeted Agents in AML Towards more drug-like proteomimetics: two-faced, synthetic α-helix mimetics based on a purine scaffold.BIRC6 mediates imatinib resistance independently of Mcl-1.The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells.Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells.Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells.Holotoxin A₁ Induces Apoptosis by Activating Acid Sphingomyelinase and Neutral Sphingomyelinase in K562 and Human Primary Leukemia Cells.

P2860

Q28076011-CB072025-5A0D-4D2D-86C0-6045695B6B99 Q28269486-D5543BE9-9FC7-473F-B0B9-EF211BED6AC4 Q30275460-5FA7316D-3A54-4A11-8451-F4A3D05E302F Q33779684-5CF8C6B1-2DAC-4521-BFD0-38C9EAFA2111 Q34991284-5C6B8A52-0B3B-45C1-83D1-A78A0FE68E44 Q35007971-AC83C066-C89C-4CD3-B8AD-ABDC852CDF68 Q35742361-A1359EEE-7864-4653-9835-0C25E77F691B Q35750491-B4EAB2D0-5D53-4025-B1BC-D8BE7F44CB83 Q35926303-56636E59-E0AB-4F21-91FE-99DE8CDF58F0 Q36375641-E272D1C2-9CC7-4168-83DA-D25EF6BBB2ED Q36992184-2D0FB3B3-17F6-4667-A3B7-BE53B01146D2 Q37399378-66EA9C36-93D3-429C-B8A6-D88051BD8328 Q38537879-DC47FC7C-40BB-4A87-8E4A-C8290CF6D4AC Q38730327-69BCBDC4-66FE-4454-86BB-737ED75309E8 Q54969772-659CE760-7445-4C09-8AD2-2C629EF0ED29

P2860

Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML).

http://www.wikidata.org/entity/Q37104378

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML).

@en

Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia

@nl

type

label

Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML).

@en

Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia

@nl

prefLabel

Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML).

@en

Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia

@nl

P1433

Q37104378-66AF202F-0B98-4964-BBE1-72576C3BDCCF

P1476

Q37104378-C1F0A63F-ABFD-4278-85D8-539756498A6C

P2093

Q37104378-8ED12C93-7FD5-4917-B92F-7C6C5CBB7A9C

Q37104378-9DDE7868-FEFC-4CBC-9222-55E6D26B8CD3

P2860

Q37104378-01BFF718-568A-44B1-9DE7-2CFCA0507EB2

Q37104378-023B3F39-BEC7-4656-B3FE-0EE290D2E21E

Q37104378-1E74DBFE-7C00-491C-8E12-80199E214F3E

Q37104378-5426D8CC-7FEF-4BD8-A217-07DE2C3D7DF8

Q37104378-621B7E22-93D1-48BE-8786-AE08E4A74400

Q37104378-6E4C7646-5A05-46C8-92CE-984BF1738346

Q37104378-71D59DE3-1675-4C23-B483-45354DF34F41

Q37104378-B0E16E84-CA89-4FAB-B9FA-F99DE251FB6C

Q37104378-B9634603-3EDC-41CE-A786-0301596C3322

Q37104378-BCAE7756-A13C-49CD-934C-067F5EE35B77

P304

Q37104378-C8562F02-F905-4949-9E01-4E890F352F7B

P31

Q37104378-50BFE294-76BE-41B6-989B-25572B9069DA

P356

Q37104378-9C0466CC-EE2B-427B-8BBA-197145837C85

P433

Q37104378-28B9DA05-B6FA-47A7-8E2D-7FACB5929D19

P478

Q37104378-610D6EB2-7759-45DD-B960-C1DB128AE3D0

P577

Q37104378-2DF36AE2-B02F-4278-B930-FD3923D6F98A

P5875

Q37104378-0C55D76F-8699-47CA-8464-37AADAE64764

P698

Q37104378-134CE050-4B70-4002-8E91-D36AA5686F25

P921

Q37104378-ECFB0677-FA74-4338-89BF-DF0B89DA5067

P932

Q37104378-357ACDA4-17C2-4435-B80D-2015AE63FE9D

P356

J.LRR.2012.11.006

P1433

Leukemia research reports

P1476

Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML).

@en

P2093

Prithviraj Bose

http://www.w3.org/2001/XMLSchema#string

Steven Grant

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).

Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.

Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies.

Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.

MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

P304

12-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.LRR.2012.11.006

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256103024

http://www.w3.org/2001/XMLSchema#string

P698

23977453

http://www.w3.org/2001/XMLSchema#string

P921

P932

3747011

http://www.w3.org/2001/XMLSchema#string